Zobrazeno 1 - 10
of 95
pro vyhledávání: '"Kathleen Blondeau"'
Autor:
Brian Weinshenker, Michael R. Yeaman, Jerome de Seze, Francesco Patti, Ivana Vodopivec, Kathleen Blondeau, Gaëlle Klingelschmitt, Carole Marcillat, Benjamin M. Greenberg, Shervin Gholizadeh
Publikováno v:
Thursday, April 27.
Autor:
Amanda Roden, Nan Hu, Logan Brooks, Monica K Wetzel-Smith, Montserrat Carrasco-Triguero, Geoffrey A. Kerchner, Michael J. Dolton, Kathleen Blondeau, Jill Smith, Ariel Waitz, Anita Moein, Kaycee M Sink, Angelica Quartino, Aaron Chesterman, Kun Peng, Ajay Deshmukh, Susanne Ostrowitzki
Publikováno v:
Clinical Pharmacology & Therapeutics. 110:1337-1348
Compared with intravenous formulations, subcutaneous (s.c.) formulations of therapeutic monoclonal antibodies may provide increased patient access and more convenient administration options, although historically high-volume s.c. administration (> 10
Autor:
Susanne Ostrowitzki, Tobias Bittner, Kaycee M. Sink, Howard Mackey, Christina Rabe, Lawrence S. Honig, Emanuele Cassetta, Michael Woodward, Mercè Boada, Christopher H. van Dyck, Timo Grimmer, Dennis J. Selkoe, Andres Schneider, Kathleen Blondeau, Nan Hu, Angelica Quartino, David Clayton, Michael Dolton, Yifan Dang, Beth Ostaszewski, Sandra M. Sanabria-Bohórquez, Michael Rabbia, Balazs Toth, Udo Eichenlaub, Jillian Smith, Lee A. Honigberg, Rachelle S. Doody
Publikováno v:
JAMA neurology. 79(11)
ImportanceAlzheimer disease (AD), a neurodegenerative disease characterized by β-amyloid plaques and τ tangles in the brain, represents an unmet medical need with no fully approved therapeutics to modify disease progression.ObjectiveTo investigate
Publikováno v:
Alzheimer's & Dementia. 16
Autor:
Susanne Ostrowitzki, Jillian Smith, Angelica Quartino, Michael J. Dolton, Lawrence S. Honig, Montserrat Carrasco-Triguero, Tobias Bittner, Heather Guthrie, Helen Lin, David Clayton, Kathleen Blondeau, Qinshu Lian, Kaycee M Sink
Publikováno v:
Journal of Alzheimer's Disease
Background Crenezumab is a fully humanized, monoclonal anti-amyloid-β immunoglobulin G4 antibody. Objective This Phase Ib study (NCT02353598) evaluated the safety, tolerability, and pharmacokinetics of crenezumabat doses of ≤120 mg/kg administered
Publikováno v:
Expert Opinion on Emerging Drugs. 17:347-359
Proton pump inhibitors (PPIs) have considerably improved quality of life in patients with gastroesophageal reflux disease (GERD). However, many patients remain symptomatic despite standard PPI therapy.This review focuses on evolving therapeutic strat
Autor:
Marijke Proesmans, Ann Decraene, Daniel Sifrim, Veerle Mertens, Ans Pauwels, Ricard Farré, Pascal Van Bleyenbergh, Lieven Dupont, Kathleen Blondeau
Publikováno v:
Chest. 141:1568-1574
Up to 80% of patients with cystic fibrosis (CF) may have increased gastroesophageal reflux and aspiration of duodenogastric contents into the lungs. We aimed to assess aspiration in patients with CF by measuring duodenogastric components in induced s
Autor:
Nathalie Rommel, R. Farré, Guy E. Boeckxstaens, Lieselot Holvoet, Kathleen Blondeau, Stephanie Depeyper, Veerle Boecxstaens, Jan Tack
Publikováno v:
Clinical Gastroenterology and Hepatology. 10:379-384
Background & Aims In patients with clinically suspected rumination, esophageal impedance manometry differentiates episodes of rumination (involuntary straining with intragastric pressure increases) from aerophagia/supragastric belching. Treatment opt
Autor:
Dirk Vanbeckevoort, Willy Coosemans, Guy E. Boeckxstaens, Jan Tack, Kathleen Blondeau, Toni Lerut, Tim Vanuytsel
Publikováno v:
Clinical Gastroenterology and Hepatology. 10:142-149
Esophageal perforation is the most serious adverse event of pneumatic dilation (PD) for achalasia; it is usually managed by surgical repair. We investigated risk factors for esophageal perforation after PD and evaluated safety and long-term outcome o
Autor:
A Papathanasopoulos, Veerle Boecxstaens, Rita Vos, Ricard Farré, Nathalie Rommel, M di Stefano, Kathleen Blondeau, Jan Tack
Publikováno v:
Diseases of the Esophagus. 25:470-476
There are limited data concerning the effects of 5-HT(1A) receptor activation on esophageal motility. Sumatriptan, a 5-HT(1A) receptor agonist, was recently reported to enhance esophageal peristalsis after intravenous administration. Buspirone, an or